Luminex, Merck to develop companion Dx for Alzheimer's drug

03/14/2013 | GenomeWeb Daily News (free registration) · Fox Business

Luminex and Merck & Co. have entered a partnership to develop a companion test for the latter's MK-8931, an investigational drug for Alzheimer's disease. The test will be used to screen patients for a clinical trial of MK-8931. The assay will assess levels of two potential disease biomarkers in cerebrospinal fluid samples from patients who demonstrate mild cognitive impairment.

View Full Article in:

GenomeWeb Daily News (free registration) · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care